The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1 -Dependent Pathway in Multiple Myeloma

(2009) J. Zhang et al.   CANCER RESEARCH

Biological Therapies for Inflammatory Bowel Diseases

(2009) Paul Rutgeerts et al.   GASTROENTEROLOGY

ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology

(2008) R. Schmidmaier et al.   CURRENT MEDICINAL CHEMISTRY

Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4–VCAM-1 adhesion and macrophage inflammatory protein-1α and MIP-1β production

(2008) Masahiro Abe et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

(2008) K Hatano et al.   ONCOGENE